首页 | 本学科首页   官方微博 | 高级检索  
检索        


The impact of age on ablation outcomes in AF-mediated cardiomyopathy
Authors:Louise Segan MBBS  David Chieng MBBS  Hariharan Sugumar MBBS  PhD  Aleksandr Voskoboinik MBBS  PhD  Liang-Han Ling MBBS  PhD  Ben Costello MBBS  PhD  Sonia Azzopardi RN  Ziporah Nderitu RN  Ramanathan Parameswaran MBBS  PhD  John Amerena MBBS  Alex J McLellan MBBS  PhD  Geoffrey Lee MBChD  PhD  Joseph Morton MBBS  PhD  Stephen Joseph MBBS  Michael Wong MBBS  PhD  Andrew Taylor MBBS  PhD  Jonathan M Kalman MBBS  PhD  Peter M Kistler MBBS  PhD  Sandeep Prabhu MBBS  PhD
Institution:1. The Baker Heart and Diabetes Research Institute, Melbourne, Australia

The Alfred Hospital, Melbourne, Australia

University of Melbourne, Melbourne, Australia

Cabrini Hospital, Melbourne, Australia;2. The Baker Heart and Diabetes Research Institute, Melbourne, Australia

The Alfred Hospital, Melbourne, Australia

University of Melbourne, Melbourne, Australia

Cabrini Hospital, Melbourne, Australia

Western Health, Melbourne, Australia;3. The Baker Heart and Diabetes Research Institute, Melbourne, Australia

Western Health, Melbourne, Australia;4. The Baker Heart and Diabetes Research Institute, Melbourne, Australia

The Alfred Hospital, Melbourne, Australia;5. University of Melbourne, Melbourne, Australia

Royal Melbourne Hospital, Melbourne, Australia

Barwon Health, Geelong, Australia;6. Barwon Health, Geelong, Australia;7. University of Melbourne, Melbourne, Australia

Royal Melbourne Hospital, Melbourne, Australia;8. University of Melbourne, Melbourne, Australia;9. Western Health, Melbourne, Australia;10. University of Melbourne, Melbourne, Australia

Western Health, Melbourne, Australia

Royal Melbourne Hospital, Melbourne, Australia;11. The Alfred Hospital, Melbourne, Australia;12. The Baker Heart and Diabetes Research Institute, Melbourne, Australia

Abstract:

Introduction

The absence of ventricular scar in patients with atrial fibrillation (AF) and systolic heart failure (HF) predicts left ventricular (LV) recovery following AF ablation. It is unknown whether age impacts the degree of LV recovery, reverse remodeling, or AF recurrence following catheter ablation (CA) among this population.

Objectives

To evaluate the impact of age on LV recovery and AF recurrence in a population with AF and systolic HF without fibrosis (termed AF-mediated cardiomyopathy) following CA.

Methods

Consecutive patients undergoing CA between 2013 and 2021 with LV ejection fraction (LVEF) < 45% and absence of cardiac magnetic resonance imaging (CMR) detected LV myocardial fibrosis were stratified by age (<65 vs. ≥65 years). Following CA, participants underwent remote rhythm monitoring for 12 months with repeat CMR for HF surveillance.

Results

The study population consisted of 70 patients (10% female, mean LVEF 33 ± 9%), stratified into younger (age < 65 years, 63%) and older (age ≥ 65 years, 37%) cohorts. Baseline comorbidities, LVEF (34 ± 9 vs. 33 ± 8 ≥65 years, p = .686), atrial and ventricular dimensions (left atrial volume index: 55 ± 21 vs. 56 ± 14 mL/m2 age ≥ 65, p = .834; indexed left ventricular end-diastolic volume: 108 ± 40 vs. 104 ± 28 mL/m2 age ≥ 65, p = .681), pharmacotherapy and ablation strategy (pulmonary vein isolation in all; posterior wall isolation in 27% vs. 19% age ≥ 65, p = .448; cavotricuspid isthmus in 9% vs. 11.5% age ≥ 65) were comparable (all p > .05) albeit a higher CHADS2VASc score in the older cohort (2.7 ± 0.9 vs. 1.6 ± 0.6 age < 65, p < .001).   Freedom from AF was comparable (hazard ratio: 0.65, 95% confidence interval: 0.38–1.48, LogRank p = .283) as was AF burden 0% (interquartile range, IQR: 0.0–2.1) vs. age ≥ 65: 0% (IQR 0.0–1.7), p = .516], irrespective of age. There was a significant improvement in LV systolic function in both groups (ΔLVEF + 21 ± 14% vs. +21 ± 12% age ≥ 65, p = .913), with LV recovery in the vast majority (73% vs. 69%, respectively, p = .759) at 13 (IQR: 12–16) months. This was accompanied by comparable improvements in functional status (New York Heart Association class p = .851; 6-min walk distance 50 ± 61 vs. 93 ± 134 m in age ≥ 65, p = .066), biomarkers (ΔN-terminal-pro brain natriuretic peptide ?139 ± 246 vs. ?168 ± 181 age ≥ 65,p = .629) and HF symptoms (Short Form-36 survey Δphysical component summary p = .483/Δmental component summary, p = .841).

Conclusion

In patients undergoing CA for AF with systolic HF in the absence of ventricular scar, comparable improvements in ventricular function, symptoms, and freedom from AF are achieved irrespective of age.
Keywords:AF-mediated cardiomyopathy  atrial fibrillation  catheter ablation  elderly  heart failure  myocardial fibrosis
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号